ARS Pharmaceuticals (SPRY) Current Assets (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Current Assets data on file, last reported at $245.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 19.29% year-over-year to $245.2 million; the trailing twelve-month figure through Mar 2026 stood at $245.2 million (down 19.29% YoY), and the FY2025 full-year result was $284.9 million, down 14.78% from the prior year.
• Current Assets declined to $245.2 million in Q1 2026, from $284.9 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $338.9 million in Q3 2025 to a low of $208.8 million in Q3 2024.
• A 5-year average of $265.6 million and a median of $263.1 million in 2022 frame the typical range for Current Assets.
• Peak annual rise in Current Assets reached 357.27% in 2022, while the deepest fall reached 30.93% in 2022.
• Tracing SPRY's Current Assets over 5 years: stood at $277.7 million in 2022, then decreased by 16.56% to $231.7 million in 2023, then jumped by 44.26% to $334.3 million in 2024, then declined by 14.78% to $284.9 million in 2025, then decreased by 13.92% to $245.2 million in 2026.
• Business Quant data shows SPRY's Current Assets at $245.2 million in Q1 2026, $284.9 million in Q4 2025, and $338.9 million in Q3 2025.